Výsledky vyhledávání - "Elliot A. Warner"

Supplementary Data from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma

Autor: Nicholas K. Foreman, Kathleen Dorris, Rajeev Vibhakar, Michael H. Handler, Todd C. Hankinson, Lindsey M. Hoffman, Jean M. Mulcahy Levy, Davis A. Witt, Andrea M. Griesinger, Elliot A. Warner, Vladimir Amani, Andrew M. Donson

FDA panel: Details of drug screen library of 97 FDA approved anticancer active compounds. FDA drug targets: Genes corresponding to known protein targets of compounds in FDA approved oncology drug screen library, corresponding Affymetrix probeset IDs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0934b7c0f66676aadd367af2ec952d83
https://doi.org/10.1158/1535-7163.22505077

Zobrazit plný text záznamu

Data from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma

Children with ependymoma (EPN) are cured in less than 50% of cases, with little improvement in outcome over the last several decades. Chemotherapy has not affected survival in EPN, due in part to a lack of preclinical models that has precluded compre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::51f1a1cf1f21b6a7bd704b6f85b92aff
https://doi.org/10.1158/1535-7163.c.6537940.v1

Zobrazit plný text záznamu

Supplementary Figure 2 from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma

Apoptosis time courses for EPN cell lines 811 and 928 treated with floxuridine, bexarotene, and axitinib all at 1µM, as measured by live cell imaging (IncuCyte) ofcaspase 3/7 activation (green objects/mm2). Idarubicin (1µM) provides a positive cont

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a24f5660d14c9159a000724c4493f53
https://doi.org/10.1158/1535-7163.22505074.v1

Zobrazit plný text záznamu

Supplementary figure 1 from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma

Expression of EPN-selective drug targets in primary PFA patient samples versus cerebellum. Gene expression for (A) RARB, (B) PDGFRB, (C) VEGFR2 (KDR) and (D) VEGFC in twelve PFA patient samples and 4 pediatric cerebellum samples. Red bars represent m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d02bc6db6ee4a387bd7927d4a8a8e88
https://doi.org/10.1158/1535-7163.22505071

Zobrazit plný text záznamu

Identification of FDA-approved oncology drugs with selective potency in high-risk childhood ependymoma

Autor: Vladimir Amani, Kathleen Dorris, Todd C. Hankinson, Nicholas K. Foreman, Davis Witt, Jean M. Mulcahy Levy, Michael H. Handler, Lindsey M. Hoffman, Andrew M. Donson, Andrea Griesinger, Rajeev Vibhakar, Elliot A. Warner

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05fd494e21caefc51faf354908dc6272
https://europepmc.org/articles/PMC6125158/

Zobrazit plný text záznamu

Statistical Coupling Analysis-guided library design for discovery of mutant luciferases

Autor: Aaron M. Leconte, Charlotte E. Morrissey, Colin M. Rathbun, Gabriela V. Ochoa, Marya Y. Ornelas, Taia S. Wu, Jennifer A. Prescher, Mira D. Liu, Elliot A. Warner, Caitlyn W. Fick, Brendan S. Zhang, William B. Porterfield

Publikováno v: Biochemistry, vol 57, iss 5

Directed evolution has proven to be an invaluable tool for protein engineering; however, there is still a need for developing new approaches to continue to improve the efficiency and efficacy of these methods. Here, we demonstrate a new method for li

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d41731eaed5b93ba06d6a41e3fff94f5
https://europepmc.org/articles/PMC6192264/

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání